Non-interventional Cohort Study of Patients Treated With Liso-cel (Lisocabtagene Maraleucel) for Relapsed/Refractory Follicular Lymphoma in the Postmarketing Setting
Latest Information Update: 03 Feb 2025
Price :
$35 *
At a glance
- Drugs Lisocabtagene-maraleucel (Primary)
- Indications Follicular lymphoma
- Focus Adverse reactions
- Sponsors Juno Therapeutics
- 03 Feb 2025 New trial record